There was a significant decrease in MADRS scores over
the course of treatment (F = 11.17; df = 3, 17; p < 0.0005).
The improvement from baseline was significant at week 2
and remained so through to week 8 (Figure 1). On
intention-to-treat at study endpoint, pooled MADRS
scores reduced from 20.45(±7.78) to 14.05(±8.68),
with a reduction of 6.40 points. Similarly, CGI-S scores
significantly decreased over the course of study (F = 15.84;df = 3, 17; p < 0.0005), and again, this was significant from
week 2 through to week 8. No correlation was found between
the dose of aripiprazole and reduction of MADRS
or CGI-S scores. There was no significant difference in
YMRS scores over the study. Observed case analysis
resulted in similar findings. Eight (40%) patients met
MADRS response criteria while seven (35%) patients were
classified as MADRS remitters at the last evaluation,
whereas seven (50%) of the 14 patients who completed
8 weeks were classified as both responders and remitters.